Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.69 |
| ▸ | CTSS | P25774 | 14/20 | 0.53 |
| ▸ | CTSK | P43235 | 12/20 | 0.53 |
| ▸ | CTSB | P07858 | 7/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 4/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818080 | 1.00 | CTSL (0.69) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL29168115 | 1.00 | CTSL (0.69) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL30461919 | 0.86 | CTSL (0.74) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL1519627 | 0.86 | CTSL (0.74) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL3553561 | 0.86 | CTSL (0.74) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL1519629 | 0.86 | CTSL (0.74) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL29855016 | 0.85 | CTSL (0.69) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL5403852 | 0.85 | CTSL (0.69) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL4917443 | 0.85 | CTSL (0.69) | CTSLCTSSCTSKCTSBACE | |
| SCHEMBL16460171 | 0.82 | CTSL (0.66) | CTSLCTSSCTSKCTSBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| EP-4352049-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Avelos Therapeutics Inc. (KR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | CTSL 643/4885CTSS 1147/4885CTSK 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.